Clinical trials: MS
Idiopathic Lung Fibrosis, Idiopathic Pulmonary Fibrosis
Breath Analysis in Lung Fibrosis
The aim of the study is to answer the question whether a disease specific profile of breath in patients with idiopathic lung fibrosis can be detected by an untargeted metabolomic study using exhaled breath analysis by mass…
- Trial name
- NCT02437448
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Multiple Sclerosis
Evaluation of the Microbiome in Multiple Sclerosis
To access the small intestinal microbiome and find abnormal microbiome/metabolome signature in luminal fluid samples from small bowel in MS compared to HC that could be used as biomarkers for MS.
- Trial name
- NCT05844826
- Testing
- SIMBA Capsule
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Nimble Science Ltd.
Sepsis With Escherichia Coli
Rapid Detection of Bacterial Resistance by MALDI-TOF MS and Antibiotic Savings
This study aims at determining within a short time (<3h) the susceptibility to clinical isolates of E. coli to the major antibiotics directly from positive blood cultures.
- Trial name
- MALDI-TRAc (NCT02860247)
- Volunteers
- 103 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Multiple Sclerosis
Vitamin D3 and the Stress-axis in MS
Patients with multiple sclerosis (MS) have an increased risk of developing a major depression. The investigators observed a protective effect of high vitamin D levels on the risk of depression in MS.
- Trial name
- NCT02096133
- Testing
- Cholecalciferol
- Where
- 2 sites in Netherlands
- Volunteers
- 54 people
- Sponsor
- Academic MS Center Limburg
Healthy
Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy Volunteers
The objective of this study was to assess safety, pharmacokinetics and the effect of BIBR 953 ZW on coagulation parameters of BIBR 953 ZW after oral single doses of the prodrug, BIBR 1048 MS, in healthy male subjects.
- Trial name
- NCT02170116
- Testing
- BIBR 1048 MS dose 1, BIBR 1048 MS dose 2, BIBR 1048 MS dose 3
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Multiple Sclerosis (MS)
Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis
At-home use of Natalizumab in multiple sclerosis (MS) patients has been temporarily granted by French security agency of medicines and Health products (ANSM).
- Trial name
- Tys at Home (NCT04777539)
- Testing
- At-home natalizumab treated MS patient
- Where
- 21 sites in France
- Volunteers
- 283 people
- Sponsor
- Nantes University Hospital
Multiple Sclerosis
Safety of Bryostatin in Patients With MS
This is a single-site, single-arm, single-dose, Phase 1 study of the safety of bryostatin in participants with multiple sclerosis (MS) receiving any disease modifying therapy (DMT).
- Trial name
- NCT06190912
- Testing
- Bryostatin 1
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Robert Fox
Multiple Sclerosis
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study is to determine the safety and tolerability of ELND002 in patients with relapsing forms of secondary progressive multiple sclerosis (SPMS) or relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT01144351
- Testing
- ELND002
- Where
- 20 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Elan Pharmaceuticals
Multiple Sclerosis
TRPMS to Improve Mobility and Depression in Multiple Sclerosis
This study is aimed to test the efficacy of 10 sessions of Transcranial Rotating Permanent Magnetic Stimulation (TRPMS) paired with aerobic exercise or computerized cognitive training (CT) on mobility and depression symptoms in…
- Trial name
- NCT04578041
- Testing
- TRPMS (Transcranial Rotating Permanent Magnet Stimulation), Aerobic Exercise Program, Computerized CT (Cognitive Training)
- Sponsor
- NYU Langone Health
C10.114.375.500
Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration
The study design matches with a multicenter observational ambispective study. A first pilot study will be undertaken in Caen center and is expected to be extended to Rouen and Lille center.
- Trial name
- PREMISEP (NCT03308994)
- Testing
- Delay between MS onset and introduction of first line DMT, EDI
- Where
- 4 sites in France
- Volunteers
- 650 people
- Sponsor
- University Hospital, Caen
Multiple Sclerosis
Pilot Study of tSCS for Improving Upper Limb Function in People With Multiple Sclerosis
The goal of this clinical trial is to evaluate whether non-invasive spinal cord neuromodulation with the SCONE™ device can improve upper limb function in people with multiple sclerosis.
- Trial name
- tSCS-MS (NCT07152145)
- Testing
- Active stimulation tSCS, Occupational/Upper Limb Rehabilitation Therapy
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Parc de Salut Mar
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1.
- Trial name
- NCT07225361
- Testing
- Ublituximab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Northwestern University
Multiple Sclerosis
Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis
Patients who have been diagnosed with clinically isolated syndrome (CIS) often develop problems related to the central nervous system, which controls the nerves in the body.
- Trial name
- STAYCIS (NCT00094172)
- Testing
- Atorvastatin
- Where
- 14 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis, Relapsing-Remitting
Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.
HLA-DRB1 * Gene and some genes involved in inflammation and immunity (IL-7R, GPC5, CTSS) have been linked to risk of MS and the response to treatment with immunomodulators.
- Trial name
- WESTEMDRB1 (NCT02769767)
- Testing
- Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.
- Where
- Mexico
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Instituto Jalisciense de Cancerologia
Multiple Sclerosis
Allocentric Memory in MS and Resting State Functional MRI
The goals of this study are to 1. Investigate the sensitivity of allocentric visual memory when compared to more established measures of cognition in identifying cognitive difficulties among MS subjects when compared to controls.
- Trial name
- NCT02118298
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Yale University
Multiple Sclerosis
Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis
This study will use positron emission tomography (PET) to measure a brain protein called peripheral benzodiazepine receptor (PBR) in patients with multiple sclerosis.
- Trial name
- NCT00432900
- Testing
- [(11)C]PBR28
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Secondary Progressive Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
The purpose of this study was to understand whether participants could mount an immune response to SARS-CoV-2 modRNA vaccines administered either during continuous siponimod treatment or during a treatment break versus while on…
- Trial name
- AMA-VACC (NCT04792567)
- Testing
- BAF312, Baseline disease modifying therapies (DMTs), BNT162
- Where
- 10 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Molecular Imaging of NET Using [C-11]MRB-PET in MS
This study aims to use [C-11]MRB PET (positron emission tomography) imaging to look at brain injury in patients with Multiple Sclerosis (MS) and healthy individuals.
- Trial name
- NCT03207464
- Testing
- [C-11]Methylreboxetine
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Relapsing-Remitting Multiple Sclerosis
High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study
The purpose of this study is to determine the effectiveness of a new treatment for multiple sclerosis (MS), a serious disease in which the immune system attacks the brain and spinal cord.
- Trial name
- NCT00288626
- Testing
- Granulocyte-colony stimulating factor (G-CSF) and prednisone, Carmustine, etoposide, cytarabine, and melphalan (BEAM), Autologous hematopoietic stem cell transplant
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)